Bronchopleural fistula is a rare but potentially fatal complication that can occur after surgery in patients receiving neoadjuvant immunochemotherapy for stage III NSCLC.
The first case of severe megaloblastic anemia in a patient treated with erlotinib for advanced NSCLC. It highlights the need for close clinical and blood monitoring in people receiving long-term TKI therapy.
Phase 2 data point to a favorable benefit–risk balance of stereotactic ablative radiotherapy in many patients with early-stage NSCLC and interstitial lung disease.
Great progress has been made in developing strategies to manage malignant pleural effusion, but these still primarily focus on optimal drainage. More research is needed to advance understanding of mechanistic drivers and develop targeted therapies.
Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.
Pleural Mesothelioma (PM) is a primary malignancy of the pleural surface, associated with prior occupational or environmental asbestos exposure. Latency period is 20–50 years between exposure and disease presentation. In 2020, 30,870 PM cases were …
TIGIT, a co-inhibitory receptor found on T cells and NK cells, transmits inhibitory signals upon binding to its ligand. This interaction suppresses the activation of various signaling pathways, leading to functional exhaustion of cells, ultimately …
The loss of appetite, anorexia, and weight loss is a common complication in patients with cancer [ 1 ]. Cachexia, defined as the loss of body weight and lean body mass [ 2 ], is associated with fatigue, weakness, decreased physical performance and …
Antibody-drug conjugates (ADCs) are an emerging class of therapeutics for lung cancer, and several are currently in development for this malignancy. The structure of these molecules is based on an antibody that targets a protein on the lung cancer …
The ADAURA trial has, as of this year, demonstrated an overall survival benefit with the adjuvant use of osimertinib in people with resectable NSCLC.
We take an in-depth look at the study with Dr. Luis Paz-Ares, who outlines the study findings, discusses the clinical implications, and addresses the pertinent questions raised by the trial.
Bronchopleural fistula is a rare but potentially fatal complication that can occur after surgery in patients receiving neoadjuvant immunochemotherapy for stage III NSCLC.
The first case of severe megaloblastic anemia in a patient treated with erlotinib for advanced NSCLC. It highlights the need for close clinical and blood monitoring in people receiving long-term TKI therapy.
A collaborative program highlighting the importance of molecular assessments and targeted treatment selection in people with biomarker-positive disease. Submit your questions for the experts now.
Expert-led, multiformat program which will address the individualized management of NSCLC, through education on the detection of NTRK gene fusions, current evidence-based guidelines, and new and emerging therapies. Will also include guidance on integrating shared decision making into your clinical practice, drawing on insights from a patient on how best to communicate.
Five-year US survival rates for lung cancer fall from 73% at stage I to 9–13% at stages IIIB and IV. [ 1 ] Hence, early diagnosis is critical to reducing mortality. Pulmonary nodules are often the first sign. [ 2 ] Around 5% of nodules 4–30 mm in …
Lung cancer remains the leading cause of cancer death worldwide, with an estimated 2.38 million new cases and 1.27 million fatalities in 2023 [ 1 ]. Early detection through imaging, particularly through chest computed tomography (CT) scans, is …
Antibody-drug conjugates (ADCs) are an emerging class of therapeutics for lung cancer, and several are currently in development for this malignancy. The structure of these molecules is based on an antibody that targets a protein on the lung cancer …
Molecular profiling of circulating tumor DNA (ctDNA) to guide treatment decisions has found its way into routine management of patients with advanced cancer. This represents a pivotal advancement in precision oncology, offering a non-invasive and …